Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows

Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows
Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings were presented in a poster titled, "Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study," at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held Sept. 25-28 in Paris. Bempegaldesleukin, developed by Nektar Therapeutics, is an investigational first-in-class agent that targets CD122, a protein found on the surface of immune T cells and natural killer (NK) cells. It works by activating and stimulating the growth of these cancer-killing immune cells, without over-activating the entire immune system. PIVOT-02 (NCT02983045) is a multi-center, open-label, Phase 1/2 trial that is assessing the safety and efficacy of bempegaldesleukin in combination with Opdivo, an immune checkpoint inhibitor developed by Brist
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.